Advances in diagnosing and managing antibody-mediated rejection.
Antibody-mediated rejection (AMR) is a unique, significant, and often severe form of allograft rejection that is not amenable to treatment with standard immunosuppressive medications. Significant advances have occurred in our ability to predict patients at risk for, and to diagnose, AMR. These advances include the development of newer anti-human leukocyte antigen (HLA)-antibody detection techniques and assays for non-HLA antibodies associated with AMR. The pathophysiology of AMR suggests a prime role for antibodies, B cells and plasma cells, but other effector molecules, especially the complement system, point to potential targets that could modify the AMR process. An emerging and potentially larger problem is the development of chronic AMR (CAMR) resulting from de novo donor-specific anti-HLA antibodies (DSA) that emerge more than 100 days posttransplantation. Therapeutic options include: (1) High-dose intravenously administered immunoglobulin (IVIG), which has many potential benefits. (2) The use of IVIG+rituximab (anti-CD20, anti-B cell). (3) The combination of plasmapheresis (PP)+low-dose IVIG with or without rituximab. Data support the efficacy of all of the above approaches. Newer approaches to treating AMR include using the proteosome inhibitor (bortezomib), which induces apoptosis in plasma cells, and eculizumab (anti-C5, anticomplement monoclonal antibody).
Jordan
Stanley C
SC
The Transplant Immunotherapy Program, Comprehensive Transplant Center, Los Angeles, CA 90048, USA. sjordan@cshs.org
Reinsmoen
Nancy
N
Peng
Alice
A
Lai
Chih-Hung
CH
Cao
Kai
K
Villicana
Rafael
R
Toyoda
Mieko
M
Kahwaji
Joseph
J
Vo
Ashley A
AA
D006084:Graft Rejection / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D006680:HLA Antigens / Q000276:immunology; D006648:Histocompatibility / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D014184:Transplantation, Homologous
D006680:HLA Antigens